People with severe allergies in the UK now have access to a needle-free alternative for treating anaphylaxis. ALK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for EURneffy®, a ready-to-use adrenaline nasal spray, for emergency use in adults and children weighing 30kg or more.
This approval marks a first-of-its-kind treatment for the UK delivering life-saving adrenaline without the need for an injection.
A Convenient, Non-Invasive Option
EURneffy® offers a simple, non-invasive and portable alternative to traditional adrenaline auto-injectors. Designed for ease of use during emergencies, the nasal spray delivers a single, full dose of adrenaline when activated no needles, no priming, and no complicated instructions required.
Key features of EURneffy® include:
- Useful, convenient and easy to use, even in stressful situations
- Non-invasive – administered through the nose
- 30-month shelf life
- No special storage required, including resilience to freezing and heat
Clinical performance comparable to adrenaline auto-injectors (AAIs) across a range of dosing conditions
Dr Helen Evans-Howells, GP, allergy specialist and Chair of the Anaphylaxis UK Clinical and Scientific Panel, said:
“We know that many patients and carers delay or avoid using adrenaline auto-injectors due to fear, confusion or hesitancy. A nasal spray addresses these issues and could lead to quicker treatment and better outcomes. EURneffy® gives doctors and patients an important new option in managing severe allergies.”
Addressing a Critical Gap in Allergy Care
Anaphylaxis is a serious and potentially life-threatening allergic reaction that can develop within minutes of exposure to an allergen. Quick access to adrenaline is essential, yet studies show that many people with severe allergies:
- Do not carry their prescribed adrenaline auto-injectors
- Hesitate or fail to use them during an emergency
In fact, around half of patients at risk of anaphylaxis do not use adrenaline when needed, and many find current devices too intimidating or bulky to carry consistently.
By offering a needle-free, user-friendly alternative, EURneffy® could help improve adherence and ensure more patients are prepared during emergencies at home, school, work, or on the go.
Backed by Clinical Research
The MHRA’s approval was based on a large body of clinical evidence, including data from over 700 participants. Clinical trials found EURneffy® to be:
- Rapidly absorbed through the nasal lining
- Well tolerated with no serious adverse events reported
- Effective even when patients had nasal congestion or illness
The nasal spray demonstrated pharmacological outcomes comparable to auto-injectors, even during self-administration, repeat dosing, and in paediatric use.
Dr Henriette Mersebach, Executive Vice President of R&D at ALK, added:
“Our goal is to make adrenaline more accessible and easier to use for people living with severe allergies. With EURneffy®, we hope more patients and caregivers will confidently carry and use adrenaline when it matters most.”
About EURneffy®
EURneffy® is approved for the emergency treatment of anaphylaxis caused by food, insect stings, medicines and other allergens, as well as idiopathic or exercise-induced anaphylaxis. It was first approved by the European Commission in 2024, and is also authorised for use in the United States under the brand name neffy®.
